PRAME anticorps (AA 476-502)

N° du produit ABIN7875177

L’anticorps anti-PRAME Polyclonal Lapin est utilisé pour la détection de PRAME dans des échantillons de Humain. Il a été validé pour WB, FACS et IHC (p).

Aperçu rapide pour PRAME anticorps (AA 476-502) (ABIN7875177)

Antigène: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PRAME est non-conjugé

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-PRAME anticorps

Épitope: AA 476-502

Fonction: MAPE Antibody / PRAME

Purification: Antigen affinity

Immunogène: A portion of amino acids 476-502 from the human protein was used as the immunogen for the MAPE antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: The stated application concentrations are suggested starting points. Titration of the MAPE antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the MAPE antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur PRAME

Antigène: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Autre désignation: MAPE

Sujet: MAPE (Melanoma antigen preferentially expressed in tumors), also called PRAME (Preferentially expressed antigen of melanoma), is a protein that is preferentially expressed in tumors, particularly in melanoma. It plays a vital role in regulating cell proliferation, migration, and invasion, making it a promising target for therapeutic interventions. Studies have shown that the overexpression of MAPE protein is associated with aggressive melanoma subtypes, indicating its potential as a prognostic biomarker in melanoma patients.

UniProt: P78395

Pathways: Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding